Wegovy vs Trulicity: Cost and Access Head-to-Head Comparison

How These Two GLP-1 Drugs Differ at the Molecular Level

Wegovy and Trulicity both activate the glucagon-like peptide-1 (GLP-1) receptor, but the molecules behind them are distinct. Semaglutide, the active ingredient in Wegovy, is a modified human GLP-1 analogue with 94% homology to native GLP-1 and an albumin-binding fatty acid side chain that extends its half-life to approximately 165 hours 3. Dulaglutide, the active compound in Trulicity, fuses a GLP-1 analogue to an immunoglobulin G4 (IgG4) Fc fragment, producing a half-life of about 120 hours 4.

That difference in half-life and receptor binding affinity may partly explain the divergence in weight-loss outcomes observed across their respective trial programs. Semaglutide demonstrates stronger appetite suppression at the hypothalamic level in PET imaging studies, with greater reductions in food cravings and caloric intake compared to other GLP-1 receptor agonists 5. Both drugs slow gastric emptying, increase insulin secretion in a glucose-dependent manner, and suppress glucagon release. The clinical implications of these pharmacologic differences become clear when you examine their trial results side by side.

Weight Loss: Cross-Trial Comparison

Wegovy produces significantly greater weight loss than Trulicity based on available clinical evidence. The STEP-1 trial (N=1,961) randomized adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity to semaglutide 2.4 mg weekly or placebo, both plus lifestyle intervention. At 68 weeks, the semaglutide group lost 14.9% of baseline body weight versus 2.4% in the placebo group 1.

Trulicity was not designed as a weight-loss drug. The AWARD trial program studied dulaglutide at doses of 0.75 mg and 1.5 mg (and later 3.0 mg and 4.5 mg) primarily for glycemic control in type 2 diabetes. In the AWARD-11 trial, dulaglutide 4.5 mg (the highest approved dose) produced approximately 4.7 kg of weight loss at 36 weeks compared to 3.0 kg with dulaglutide 1.5 mg 6. That translates to roughly 4.5% to 5% body-weight reduction, a third of what STEP-1 demonstrated for semaglutide 2.4 mg.

No direct head-to-head randomized trial has compared Wegovy and Trulicity at their respective maximum doses. Cross-trial comparisons carry inherent limitations: different patient populations, trial durations, and baseline BMIs. Still, the magnitude of difference (roughly threefold) is large enough that most endocrinologists consider semaglutide the stronger weight-loss agent. As Dr. Robert Kushner of Northwestern University has stated, "The degree of weight loss seen with semaglutide 2.4 mg is unprecedented for a pharmacotherapy and approaches what we previously only saw with bariatric surgery" 1.

Cardiovascular Outcomes: Where Trulicity Has the Edge

Trulicity holds an FDA-approved indication for reducing major adverse cardiovascular events in adults with type 2 diabetes and established or multiple risk factors for cardiovascular disease. That indication rests on the REWIND trial.

REWIND (N=9,901) enrolled adults with type 2 diabetes who had either prior cardiovascular events or cardiovascular risk factors and randomized them to dulaglutide 1.5 mg weekly or placebo. Over a median follow-up of 5.4 years, dulaglutide reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 12% (HR 0.88, 95% CI 0.79-0.99; P=0.026) 2. The trial was notable for including patients both with and without established cardiovascular disease, a broader population than many prior GLP-1 cardiovascular outcomes trials.

Wegovy gained a cardiovascular indication in March 2024 based on the SELECT trial (N=17,604), which showed semaglutide 2.4 mg reduced MACE by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease but without diabetes 7. SELECT and REWIND studied different populations (obesity without diabetes vs. type 2 diabetes), so the results are complementary rather than directly comparable.

For patients with type 2 diabetes and cardiovascular risk, Trulicity has years of real-world use supporting its cardiovascular profile. For patients with obesity who lack a diabetes diagnosis, Wegovy's SELECT data applies more directly. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with T2D and atherosclerotic cardiovascular disease 8.

Cost at Retail: List Price and Net Price

The list price gap between these medications is smaller than many patients expect. Wegovy carries a wholesale acquisition cost (WAC) of approximately $1,349 per month. Trulicity lists at approximately $1,067 per month. Those WAC figures represent pre-rebate, pre-discount prices and do not reflect what most patients actually pay.

Net prices after manufacturer rebates to pharmacy benefit managers tell a different story. According to Drug Channels Institute data, net prices for branded GLP-1 receptor agonists run 40% to 70% below list depending on the payer and formulary tier 9. Eli Lilly and Novo Nordisk both offer savings programs that can reduce out-of-pocket costs to $25 to $150 per month for eligible commercially insured patients.

For uninsured or cash-pay patients, the full retail price applies. Some compounding pharmacies have offered compounded semaglutide at lower prices, though FDA enforcement actions and supply chain concerns have complicated that option. Dulaglutide does not have a significant compounding market because its fusion-protein structure cannot be easily replicated outside the original manufacturing process.

Patients should verify their specific copay through their pharmacy benefit manager. A drug that is $300 cheaper at list price might cost the same or more at the point of sale depending on formulary placement and tier status.

Insurance Coverage and Formulary Access

This is where the practical difference between Wegovy and Trulicity becomes most apparent for patients. Trulicity is covered on the majority of commercial insurance formularies for its type 2 diabetes indication. Most Medicare Part D plans include dulaglutide as well, though tier placement and step-therapy requirements vary by plan.

Wegovy faces a more complicated coverage picture. Many commercial insurers cover Wegovy for obesity, but prior authorization requirements are common. Typical requirements include documented BMI ≥30 (or ≥27 with a comorbidity), evidence of a failed lifestyle modification program lasting 3 to 6 months, and sometimes failure of an older anti-obesity medication such as phentermine. Medicare Part D historically excluded anti-obesity medications from coverage under a statutory exclusion, though the Treat and Reduce Obesity Act and subsequent CMS guidance have been evolving this restriction 10.

A 2024 KFF analysis found that only 25% of large employer plans covered GLP-1 receptor agonists specifically for weight management without significant restrictions. That figure is rising, but access gaps remain, particularly for Medicaid beneficiaries and the uninsured.

Patients with type 2 diabetes who also want weight loss may find it easier to obtain coverage for Ozempic (semaglutide 2.0 mg, the diabetes-indicated sibling of Wegovy) than for Wegovy itself, since the diabetes indication faces fewer coverage barriers. This is an off-label consideration that should be discussed with the prescribing clinician.

Dosing, Titration, and Practical Administration

Both Wegovy and Trulicity are self-administered once-weekly subcutaneous injections using prefilled autoinjector pens. The injection technique is nearly identical.

Wegovy follows a five-step dose escalation over 16 weeks: 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16), and the maintenance dose of 2.4 mg from week 17 onward 11. Each dose step requires a different pen strength, meaning patients fill five different prescriptions during titration.

Trulicity offers a simpler titration. Most patients start at 0.75 mg weekly and increase to 1.5 mg after 4 weeks if additional glycemic control is needed. Higher doses of 3.0 mg and 4.5 mg are available for patients who need more aggressive A1C lowering 12.

The Trulicity pen has a hidden needle design that many patients find less anxiety-inducing than other injectable devices. The Wegovy FlexTouch pen also conceals the needle during injection. Both devices are designed for ease of use, and most patients can self-inject after a single training session.

Storage requirements are similar: refrigerated at 2°C to 8°C before first use, with room-temperature stability for a limited period (Wegovy up to 28 days; Trulicity up to 14 days at room temperature).

Side Effect Profiles

GLP-1 receptor agonists share a common side-effect signature dominated by gastrointestinal symptoms. Nausea is the most frequently reported adverse event for both drugs.

In STEP-1, nausea occurred in 44% of semaglutide-treated participants versus 18% on placebo. Diarrhea occurred in 30% versus 16%, and vomiting in 25% versus 8% 1. Most GI side effects were mild to moderate in severity and peaked during dose escalation, decreasing over time at the maintenance dose. The discontinuation rate due to adverse events was 7% for semaglutide versus 3.1% for placebo.

In the REWIND trial, gastrointestinal adverse events were also the most common reason for discontinuation with dulaglutide, but overall GI event rates were lower than those seen with semaglutide 2.4 mg: nausea in approximately 15% of dulaglutide-treated patients and diarrhea in about 12% 2. The lower GI burden with dulaglutide likely reflects both the lower relative dose and the different patient population (T2D rather than obesity).

Both drugs carry a boxed warning about the risk of medullary thyroid carcinoma based on rodent studies. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis, gallbladder events, and acute kidney injury (from dehydration secondary to GI losses) are reported with both agents. The 2023 Endocrine Society clinical practice guideline on pharmacologic management of obesity recommends monitoring for these events in all patients on GLP-1 receptor agonists 13.

Who Should Choose Wegovy

Wegovy is the stronger choice for patients whose primary treatment goal is weight reduction and who do not have type 2 diabetes. The 14.9% weight loss from STEP-1 translates to clinically meaningful improvements in blood pressure, lipid panels, obstructive sleep apnea severity, and quality of life. The SELECT trial's 20% MACE reduction adds a cardiovascular argument for patients with established heart disease and obesity 7.

Candidates for Wegovy typically include adults with BMI ≥30, adults with BMI ≥27 who have at least one weight-related condition (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and patients who have not achieved adequate weight loss with lifestyle modification alone.

The main barriers are cost and access. Patients who cannot obtain insurance coverage for Wegovy may face the full retail price or need to explore manufacturer savings programs, prior authorization appeals, or alternative GLP-1 options.

Who Should Choose Trulicity

Trulicity is better suited for patients with type 2 diabetes who need glycemic control with proven cardiovascular protection. REWIND's 5.4-year follow-up provides long-duration safety and efficacy data that few GLP-1 trials can match 2. The simpler titration schedule and lower GI side-effect burden make it a practical first GLP-1 receptor agonist for patients new to injectable therapy.

Trulicity also offers a pragmatic advantage for patients with T2D whose insurers will cover dulaglutide but not semaglutide products. The American Diabetes Association lists dulaglutide among the GLP-1 receptor agonists with demonstrated cardiovascular benefit, making it a guideline-supported first-line injectable for patients with T2D and atherosclerotic cardiovascular disease or high cardiovascular risk 8.

Patients should not choose Trulicity if their primary goal is aggressive weight loss. The 4.5% to 5% body-weight reduction at the 4.5 mg dose, while clinically meaningful for metabolic parameters, does not approach the magnitude of weight loss achievable with semaglutide 2.4 mg.

Can You Switch Between Wegovy and Trulicity?

Switching between GLP-1 receptor agonists is common in clinical practice and generally safe when done under medical supervision. The Endocrine Society and ADA guidelines do not specify a mandatory washout period when switching between agents in the same class 13.

A typical approach: the last dose of the outgoing drug is given on the usual injection day, and the new drug begins on the next scheduled injection day (one week later). Dose titration for the new agent usually restarts from the lowest dose to minimize GI side effects, though some clinicians start at a mid-range dose if the patient tolerated the prior GLP-1 well.

Reasons patients switch include inadequate weight loss, intolerable side effects, insurance formulary changes, and supply shortages. The semaglutide supply disruptions of 2023-2024 prompted many Wegovy patients to temporarily switch to available alternatives including dulaglutide 10. Patients who switched reported varying degrees of weight regain, consistent with the expectation that less potent GLP-1 agonists produce less weight suppression at steady state.

According to the Obesity Medicine Association's 2024 clinical practice statement: "When switching GLP-1 RAs, clinicians should counsel patients that efficacy differences between agents are expected and that some weight fluctuation during the transition period is normal."

The Bottom Line on Choosing Between Them

The decision between Wegovy and Trulicity is primarily driven by three factors: your diagnosis (obesity vs. T2D), your insurance formulary, and your treatment priority (weight loss vs. cardiovascular/glycemic control). Neither drug is universally superior. A patient with T2D and cardiovascular risk factors who has solid Trulicity coverage is well-served by dulaglutide. A patient with obesity and no diabetes whose insurer covers Wegovy will achieve substantially more weight loss with semaglutide 2.4 mg. Discuss both options with your prescriber and run a real-time benefits check at the pharmacy before committing to either agent.